Navigation Links
Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association

Interim Data from Phase 1 Clinical Trial of SNS-595 in Acute Leukemia Demonstrates Additional Clinical Activity

SOUTH SAN FRANCISCO, Calif., June 11, 2007 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. presented positive data from clinical studies of two of the company's anti-cancer product candidates, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association (EHA) in Vienna, Austria.

Interim Results from Sunesis' Phase 1 Study of SNS-595 in Acute Leukemias

Interim data from the company's ongoing Phase 1 clinical trial of SNS-595 in patients with relapsed and/or refractory acute leukemias continue to demonstrate SNS-595's anti-cancer activity when administered on either a weekly or twice-weekly schedule. To date, on the weekly schedule, five out of ten patients in the 50 mg/m2 and 60 mg/m2 dose cohorts experienced bone marrow blast reductions of more than 95 percent, including one complete remission with incomplete platelet recovery (CRp), one complete remission in a patient who demonstrated partial but incomplete recovery of normal hematopoietic blood elements (CRi) and one partial response (PR). Additionally, in the twice-weekly 40 mg/m2 dose cohort, one of three patients had blast reduction of more than 95 percent and that patient achieved a complete remission (CR). Several patients have gone on to receive and tolerate multiple courses of treatment with SNS-595.

The data presented from the Phase 1 clinical trial of SNS-595 show a correlation between plasma drug levels, modulation of a pharmacodynamic marker of biologic activity and clinical responses when treated with SNS-595. There is emerging evidence that clinical responses are observed when plasma concentrations of SNS-595 exceed and remain above a threshold level for approximately 20 hours per week of active treatment. The CR, CRp and CRi responses observed to date all had sustained blood levels above
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
3. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
4. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
(Date:10/25/2014)... , Oct. 24, 2014 Research and ... Equipment Market Current Trends, Opportunities - Global Forecast to ... In this report, the global dental equipment market is ... dental systems and equipment market is expected to register ... during the forecast period (2014 to 2019). This high ...
(Date:10/25/2014)... 24, 2014  The National Association of Drug ... achieved by Kentucky,s real-time, ... The National Precursor Log Exchange (NPLEx) system automatically ... sale and helps flag meth offenders for law ... up NPLEx "watch lists" that notify them via ...
(Date:10/25/2014)... 2014 Burzynski Research Institute, Inc. (BRI) announced ... has given the company permission to conduct an open-label ... 3 months of age with a diffuse intrinsic brainstem ... of five treatment groups based on their age and ... DIPG. The primary study endpoint is a decrease in ...
Breaking Medicine Technology:Dental Equipment Market Current Trends, Opportunities - Global Forecast to 2019 2Dental Equipment Market Current Trends, Opportunities - Global Forecast to 2019 3Kentucky's NPLEx Technology Making Significant Progress 2Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2
(Date:10/25/2014)... -- Researchers who discovered antibiotics in farmed and ... concern. The use of antibiotics in animals, ... contribute to the development of antibiotic-resistant bacteria that ... the study. Each year in the United ... and kill about 23,000, according to the Infectious ...
(Date:10/25/2014)... 2014 (HealthDay News) -- Current osteoporosis screening guidelines ... women at risk for osteoporosis-related fractures, a new ... fractures, we need tools that help us accurately ... that we can target these at-risk people for ... of medicine in the division of general internal ...
(Date:10/25/2014)... shorter, darker days can trigger a type of depression, ... People affected by seasonal affective disorder, also ... even have trouble getting out of bed. In extreme ... Halaris, a professor in the department of psychiatry and ... Medicine. "Seasonal affective disorder should not be taken ...
(Date:10/22/2014)... On Saturday, October 25, 2014, the Brownsville ... health and fitness fair ¡Vive tu vida! Get Up! Get ... nutrition for better health and wellness for people of all ... open to the public, will be held at Dean Porter ... to 1:00 pm. , “¡Vive tu Vida! Get Up! ...
(Date:10/22/2014)... 22, 2014 Medical Solutions ... is happy to announce that our co-founder and ... Industry Analysts’ Staffing 100 for 2014. Anderson was ... most influential people in the staffing industry,” in ... the 13th-largest healthcare staffing company in the U.S., ...
Breaking Medicine News(10 mins):Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3
... researchers at the Salk Institute for Biological Studies and ... suppressor p53, long thought of as the "Guardian of ... It may also prevent established cancer cells from sliding ... a "Guardian against Genome Reprogramming." The new work, ...
... study from the Swedish medical university Karolinska Institutet sheds ... brain of the first Alzheimer,s patient to display amyloids ... during progression of the disease and after death. ... accumulation in the brain of beta-amyloid proteins to form ...
... , MONDAY, Dec. 13 (HealthDay News) -- A federal ... is unconstitutional, saying the federal government has no authority to ... is a cornerstone of the new legislation, signed into law ... was not unexpected, and both supporters and opponents of the ...
... recognized that fragmentation of medical information is a problem in ... many patients may be at risk haven,t been well quantified. ... looked at adult acute care in Massachusetts and found that ... a five-year period, almost a third sought care at two ...
... devastating side effect of chemotherapy with an innovative new program ... reduce scalp hair loss in breast cancer patients. One ... inquiry of its kind in the United States, will test ... overseas called the "DigniCap." The FDA recently approved a pilot ...
... 13 (HealthDay News) -- About 40 percent of patients ... to conventional treatments, finds a new study. German ... grade IV gliomas (tumors) about their use of alternative ... percent used homeopathy, 31 percent used vitamin supplements and ...
Cached Medicine News:Health News:The stemness of cancer cells 2Health News:The stemness of cancer cells 3Health News:Unique case study on Alzheimer's disease 2Health News:Federal Judge Strikes Down Health Reform Law 2Health News:Federal Judge Strikes Down Health Reform Law 3Health News:Quantifying fragmentation of medical information 2Health News:Quantifying fragmentation of medical information 3Health News:UCSF tests promising solutions for cancer hair loss 2Health News:UCSF tests promising solutions for cancer hair loss 3Health News:Many Brain Tumor Patients Turn to Alternative Therapies 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: